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Background: WolcottRallison syndrome (WRS) is caused by recessive EIF2AK3 gene mutations and
characterized by permanent neonatal diabetes (PNDM), skeletal dysplasia, and recurrent hepatitis. The
frequency of this rare syndrome is largely unknown.
Objectives: To define the frequency and spectrum of WRS in the Kingdom of Saudi Arabia (KSA) based on
published data.
Methods: The Medline database was searched for published articles on WRS. The number of reported cases
from KSA was compared to the total number of WRS cases reported worldwide. The genotype and
phenotype of WRS patients from KSA were reviewed.
Results: Ten articles describing 23 WRS patients from 12 Saudi families from 1995 to 2012 were identified.
This figure accounts for 27.7% (23/83) of the patients and 22.2% (12/54) of the families with WRS reported
worldwide until January 2013. All Saudi patients with WRS presented with PNDM, and they represent 59%
of all PNDM cases from WRS. At reporting, 73% of patients experienced recurrent hepatitis, 56.5% had
skeletal abnormalities, and 39.1% of them were dead. There was a variation in the phenotype even between
affected siblings. Genetic diagnosis was confirmed in all 12 families with no correlation between the genotype
and phenotype. Eight of the nine EIF2AK3 mutations were only reported in these families, and one was
shared with a patient from Qatar, a neighboring Arab state.
Conclusions: No study on the frequency of WRS has been published. However, the available data indicate that
KSA has the largest collection of patients with WRS worldwide, and nine of the identifiable EIF2AK3
mutations appear to be confined to Arabs. Establishing a national or international registry for WRS would
provide more reliable data on this rare condition.
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W
olcottRallison syndrome (WRS) is an auto-
somal recessive condition that was first de-
scribed in three children in 1972 (1). It is
characterized by permanent neonatal diabetes mellitus
(PNDM), skeletal dysplasia, and recurrent hepatitis trig-
gered by viral illnesses and stress (2). Other features such as
renal dysfunction, failure to thrive, neutropenia, exocrine
pancreatic insufficiency, hypothyroidism, recurrent infec-
tion, and developmental delay have been reported in some
patients (35). The condition has poor prognosis, with
most patients dying during childhood mainly due to acute
fulminant hepatitis and/or acute renal impairment (25).
In 2000, mutations in the EIF2AK3 gene were identified
in a few patients with WRS (5), and since then almost all
patients with classical WRS features have EIF2AK3
mutations. The EIF2AK3 gene encodes a transmembrane
protein called protein kinase R-like endoplasmic reticu-
lum kinase (PERK), which is important for the cellular
response to endoplasmic reticulum (ER) stress. The
absence of PERK activity reduces the ER’s abilities to
deal with stress, leading to cell death by apoptosis in many
tissues (6, 7). Recently, reports by Feng et al. (8) and
Gupta et al. (9) showed that acute ablation of PERK
results in reduced cell proliferation with abnormal insulin
trafficking and secretion. Studies in EIF2AK3/PERK
knockout mouse demonstrated that PERK is required for
pancreatic beta cell development during fetal and early
neonatal development (7), and that diabetes and skeletal
dysplasia are due to loss of PERK expression in pancrea-
tic beta cells (10) and osteoblasts (11).
Data on the epidemiology of WRS are limited, and the
latest literature review on the subject suggested that less
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than 60 WRS cases were reported worldwide (2). How-
ever, the condition has been recently found to be the
commonest genetic cause of PNDM in consanguineous
families (4) and in the Arab population (12). In the
Kingdom of Saudi Arabia (KSA), the population is
mostly Arab, and consanguinity is highly practiced (13);
it is therefore expected to be one of the demographic foci
for this condition. However, little is known about the
frequency or spectrum of WRS in the country. The aim of
this article is therefore to define the frequency of WRS in
KSA compared to other populations and to describe the
genetics and clinical phenotype of WRS in the country
based on reported cases in the literature.
Methods
Article collection
The Medline database was searched for articles, including
case reports and letters, using the key words ‘Wolcott
Rallison syndrome’, ‘permanent neonatal diabetes’, and
‘EIF2AK3 gene mutations’. The titles and abstracts of the
papers were scanned by the author to identify eligible
articles according to defined inclusion and exclusion
criteria. The references in selected papers were checked
for additional articles. Replication of reported cases was
excluded by patients’ demographic data and clinical
characteristics, the mutation type, and, if needed, authors’
names and institutions.
Inclusion and exclusion criteria
Articles were selected if they were written in English, were
published before 31 January 2013, and included data
on the epidemiology, phenotype, or genotype of WRS
subjects of Saudi origin. Studies including Saudi patients
with PNDM not caused by WRS or those without
clinical and demographic details were excluded.
Data extraction
The genotype, phenotype, and country of origin of
published WRS cases were retrieved from the full text of
the articles. The following data were collected and
described: mutation type, gender, gestational age, birth
weight, age at diagnosis, age at reporting or death, clinical
phenotype, and prognosis. The total number of families
and subjects with WRS from KSA was compared to
published cases from other countries and to the total
number of reported patients with PNDM from KSA.
Results
The data selection process is shown in Fig. 1. Ten articles
(five original reports) published between 1995 and 2012
met the inclusion and exclusion criteria. Of the original
articles, two papers reported Saudi patients as part of an
international WRS cohort (3, 4), one provided data on
the frequency and spectrum of WRS in one KSA region
(14), and two described studies to define the genetic
causes of Saudi subjects with a clinical phenotype of
WRS (15, 16). The five case reports (1721) were on
patients; most of them had been or were subsequently
duplicated elsewhere (Table 1). Seven of the published
Saudi patients with WRS were reported in more than one
article (Table 1).
Frequency of WRS
In total, 23 children (14 boys) with WRS from 12
Saudi families were identified (3, 4, 1421). This number
accounts for 27.7% (23/83) of patients and 22.2% (12/54)
of families with WRS reported worldwide until 31
January 2013 (1, 35, 1440). A comparison between
the number of patients and families with WRS from
KSA and those from other countries is illustrated in
Fig. 2. The 23 children with WRS represent 58.9%
of the 39 patients with PNDM reported from KSA to
date (3, 4, 1421, 4146).
Clinical phenotype
The clinical characteristics of the 23 Saudi patients are
summarized in Table 1. All children except one (8.1) were
the product of consanguineous marriages, and 60% of
them were males. Two siblings (9.1 and 9.2) were born
preterm and the rest were born at term, with a mean birth
weight of 2.52 kg. PNDM was the presenting feature in
all patients with a median age of onset at 15 weeks. There
was a variation in the frequency of other features even
between affected siblings of the same gender (Table 1). At
the time of reporting, 39.1% (9/23) of the patients were
dead, and the longest surviving patient was 9 years old.
Recurrent hepatitis was experienced in 73.9% (17/23) of
patients, and skeletal dysplasia was diagnosed in 56.5%
(13/23) of them. Thyroid dysfunction was documented in
26% (6/23) of patients: one patient developed primary
hypothyroidism in the first year of life, and the other
five had picture suggestive of central hypothyroidism.
Impaired renal function was reported in only three
subjects, and neutropenia was observed in two patients
Fig. 1. Details of data selection.
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hepatitis Other reported features and prognosis
1.1 14 V349SfsX3 (c.1044_1057del) F 2.4 10 Yes Yes Central hypothyroidism; died at 2 yr
1.2 4, 14 V349SfsX3 (c.1044_1057del) F 2.9 8 No Yes None; alive on insulin
1.3 14 V349SfsX3 (c.1044_1057del) M 3.1 6 No Yes None; died at 2 yr with acute hepatitis
2.1 14 V349SfsX3 (c.1044_1057del) F 2.0 16 Yes Yes Developmental delay, short stature, and renal
failure; died at 6 yr
2.2 14 V349SfsX3 (c.1044_1057del) M 3.1 21 Yes Yes Short stature, renal dysfunction; died at 3 yr
3.1 14 V349SfsX3 (c.1044_1057del) M 2.34 8 No Yes No other features; died at 6 yr
3.2 14 V349SfsX3 (c.1044_1057del) M 2.40 8 No Yes No other features; alive on insulin
4.1 4, 17 N420TfsX14 (c.1259delA) M 2.75 3 Yes Yes Short stature; died at 7 yr
4.2 17 N420TfsX14 (c.1259delA) F 3.2 19 No Yes Transient hypothyroidism; alive at 1.1 yr
4.3 17 N420TfsX14 (c.1259delA) M 3.1 4 No Yes Died at 1.1 yr with acute hepatitis
5.1 17 N420TfsX14 (c.1259delA) F 2.4 12 No No Transient hypothyroidism; alive at 3.5 yr
5.2 17 N420TfsX14 (c.1259delA) F 2.7 8 Yes Yes Ectopic left kidney; depressed nasal; bridge;
short neck, upward slanting of palpebral fissures;
WPW syndrome; alive at 2 yr on insulin
6.1 4 S469X
(c.1406CG)
F 2.0 4 Yes Yes Primary hypothyroidism at 1.3 yr (TSH:146.6 mU/L,
FT4B5 pmol/L), hepatomegaly; alive at 2 yr
7.1 4 R1064X (c.3190CT) M 2.8 20 Yes Yes Congenital nystagmus, microcephaly, neutropenia,
and anemia at 1 yr; alive at 4 yr
8.1 4 A159PfsX41 (c.475delG) M 3.3 6 Yes Yes Neutropenia; alive at 3 yr
9.1 15, 16, 18 E524X
(1563delGAAA)
M 1.1 at 28 wks 1 Yes No Proptosis, high arched palate, downward slanting of
palpebral fissure, hydrocephalus, blue sclera,
neurodevelopmental delay, recurrent hypoglycemia,
osteopenia, and spontaneous fracture; died at 2 yr
9.2 15 Not tested M 1.5 at 30 wks 4 No No Alive at 5 months
10.1 16, 18 IVS141G/A (sp996X1020) M 2.5 8 Yes No Severe neurodevelopmental delay, recurrent
hypoglycemia; died of renal failure at 4 yr
10.2 16 Not tested M NR 2 No No Alive at 9 yr
11.1 3, 19, 20 W164X M 2.2 6 Yes Yes Hepatomegaly, developmental delay, renal
dysfunction; alive at 6 yr
11.2 3 W164X F NR 8 NR NR Patient was too young at the time of reporting to
show other features; alive
12.1 3, 21 Fs1025X1048 F 1.7 8 Yes Yes Central hypothyroidism, hepatomegaly, depressed
nasal bridge, developmental delay; alive at 6 yr
12.2 3, 21 Fs1025X1048 M 1.1 8 Yes Yes Central hypothyroidism, mild pancreatic hypoplasia





























































































from different families. Three children were reported to
have growth failure; however, exocrine pancreatic func-
tion was not tested in any of them.
Genotype
Genetic diagnosis of WRS was confirmed in all 12 Saudi
families (Table 1), and their affected members were
homozygous for nine different EIF2AK3 mutations
spreading through the PERK protein and leading to
truncated proteins (4 nonsense, 4 frameshift, and one
deletion at exon 14/intron boundaries of the EIF2AK3
gene). Of these mutations, eight were confined to these
families, and one nonsense mutation (E523X) was also
reported in a child from Qatar (4). Three families from the
same tribe shared the same frameshift V349SfsX3 muta-
tion, and two unrelated families have an identical frame-
shift N420TfsX14 mutation. No missense mutations were
identified, and there was no correlation between the
genotype and phenotype.
Discussion
This article provides comparative data on the frequency
of WRS between different countries and reviews the
genotype and phenotype of WRS patients reported from
KSA.
Since the latest literature review on WRS by Julier and
Nicolino in 2010 (2), 8 families (14 patients) from five
countries have been reported (14, 17, 2326), making a
total number of 54 families (83 patients) reported with
this condition worldwide until January 2013. The pub-
lished data show a variation in the number of reported
families between different countries, with more cases
from populations where consanguinity is part of the
culture such as the Arab states and Turkey (Fig. 1).
Fig. 2. The number of patients and families with WRS per country of origin or residency reported until January 2013.
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This variation may be related to different factors, such as
the population size, consanguinity rate, and allele fre-
quency. It could also reflect the level of recognition of
WRS and publication interest among clinicians between
different countries.
Strikingly, 22.2% of these families were from KSA,
which has the largest collection of patients with WRS
reported for a single country, suggesting that KSA is a
hotspot for this condition. The most likely explanation
for the higher frequency of WRS in KSA compared to
other countries is the combination of a large population
and a high consanguinity rate of 56% (13). All patients
except one were the product of consanguineous mar-
riages, and the condition is the commonest cause of
PNDM in consanguineous families (4). The 23 WRS
patients represent almost 60% of the reported patients
with PNDM from KSA (2, 3, 1421, 4146). This finding
is in line with recent reports that showed that WRS is the
commonest cause of PNDM in northwest KSA (14) and
in the Arab population (12). It is expected that not all
cases with WRS in KSA were reported, and it is possible
that some patients with this condition deceased before the
diagnosis was made. Given the high birth rate and
consanguinity in KSA, the author suspects that the
reported number of WRS cases is probably underestimat-
ing the frequency of this condition in the country. There
is no doubt that launching a national survey and
establishing a registry for NDM and WRS in KSA would
raise the awareness of the condition and provide more
accurate data on the epidemiology of WRS and other
forms of NDM.
All WRS patients from KSA presented with PNDM;
however, there was a variation in the onset, nature, and
severity of other features even between affected siblings of
the same gender (Table 1). This phenomenon has been
reported in some WRS families from other countries
(3, 4) and has been attributed to various factors, such as
the presence of other modified genes, variable expression
of the EIF2AK3 gene, epigenetic factors, and variation in
management protocols. However, it is also possible that
some of these patients were still too young to show some
features, such as skeletal dysplasia and failure to thrive,
at the time of reporting, or they were not completely
assessed for less common features of WRS. Of note,
neurodevelopmental functions were not formally assessed
in most Saudi subjects, and none of them had their
stool elastase measured to diagnose exocrine pancreatic
dysfunction.
Around 40% of children from KSA were dead at the
time of reporting compared to 70% in the 10 reported
patients from Turkey (3, 4, 23, 27), which has the second
largest number of reported cases. Recurrent hepatitis
triggered by viral infection was reported in more than
70% of Saudi patients, and acute fulminant hepatitis was
the main cause of death in all deceased patients from KSA.
Recent attempts to reduce ER stress through different
mechanisms are promising (47, 48); however, it is im-
portant to ensure that families of affected children
recognize early symptoms of liver dysfunction and that
patients with WRS have a clear plan prepared to avoid
delay in starting the management of acute hepatic failure.
Liver transplantation was successfully used in one patient
with acute fulminant hepatitis and PNDM from the
United Arab Emirates (UAE) in whom the diagnosis of
WRS was later confirmed at the molecular level (4).
Interestingly, his long-term diabetes control has improved
following the transplantation (A. Deeb, personal commu-
nication). However, no patient from KSA was offered this
therapy, possibly due to the short life expectancy of these
children and the lack of international experience with liver
transplantation in the condition. Given the high mortality
and morbidity of the condition, the author suggests that
patients with WRS should be managed by a multidisci-
plinary team (consisting of an endocrinologist, a hepatol-
ogist, a geneticist, and orthopedic surgeons) and believes
that developing guidelines through a national consortium
would improve the prognosis of these children.
In the reported Saudi children with WRS, five have
thyroid function consistent with central hypothyroidism
(Table 1). However, in two patients, the changes were
transient in keeping with euthyroid sickness (ES), while in
the remaining three patients the thyroid function tests
were not repeated. The author supports the notion by
Ozbek et al. (27) and Al-Shawi et al. (17) that thyroid
dysfunction is a reflection of ES rather than a feature of
WRS. Two patients from separate families (5.2 and 9.1)
were described as having facial dysmorphism, which has
been reported only in WRS cases from KSA; however, it
was not clear whether chromosomal karyotyping was
performed to exclude other conditions associated with
these features. A long-term follow-up study would provide
more insight into the clinical phenotype and prognosis
of WRS.
The molecular diagnosis of WRS was confirmed in all
reported cases from KSA, with no correlation between
the phenotype and genotype in the 12 Saudi families
as reported in most families with WRS (3, 4, 27). Three
families from the same tribe shared the same frameshift
mutation (V349SfsX3), and two unrelated families have
the same N420TfsX mutation, indicating a founder effect
or mutation hotspot. Eight of the nine EIF2AK3 muta-
tions were identified in only these Saudi families; however,
one mutation (E523) was also reported in a child from
Qatar (4, 38). The fact that Qatar is a neighboring Arab
state raises the possibility of a founder effect. It appears
that these nine mutations are confined to Arab popula-
tions; however, a large study would confirm this possibility.
Of the EIF2AK3 mutations reported to date, four
appeared to be associated with a specific phenotype:
a delayed age of onset for diabetes was reported with
WolcottRallison syndrome in KSA
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the N656 and I650 mutations (3, 4, 31), whereas milder
courses with prolonged survivals of 32 years and 35 years
were reported with the F593 and L646 mutations,
respectively (3, 4, 29). Interestingly, all of them were
missense mutations located closer to each other on the
first kinase domain of PERK protein residue. However,
no missense mutations were identified in the Saudi
families, which could explain the early onset of diabetes
and shorter survival age in all KSA patients. Neutropenia
is another feature thought to be associated with certain
mutations (2, 3, 27). However, it was reported in only two
of three affected males from a UAE family with the
W430X mutation, and it was transient in a single affected
family member with the K150RfsX2 mutation in the
Rubio-Cabizas series (4). Out of the nine reported
mutations from KSA, neutropenia was reported with
only the R1064X and A159PfsX41 mutations; however,
these mutations are not close to each other on the PERK
protein, and each family has only one affected boy. It is
therefore difficult to conclude whether certain EIF2AK3
mutations are associated with neutropenia, at least in
Saudi families with WRS.
The diagnosis of WRS is usually made on the
combination of the typical phenotype and confirmed by
genetic testing. However, Rubio-Cabizas et al. reported
three probands with apparent isolated PNDM in whom
the molecular diagnosis was made before the appearance
of other clinical features. Of note, one of the Saudi
patients (2.1) has isolated PNDM, and the diagnosis of
WRS was made only by genetic testing at 3.5 year olds
following the presentation of her younger sister (17).
Given the high morbidity, high mortality, and frequency
of WRS in KSA, facilities for early genetic testing should
be made readily available for all patients with PNDM,
and all patients with PNDM from KSA and from other
states where consanguinity is highly practiced should be
tested for EIF2AK3 mutations regardless of their pheno-
type. Reducing consanguinity is a challenge in some
cultures such as KSA; however, antenatal diagnosis with
termination of pregnancy and pregestational diagnosis,
which allow for the selection of unaffected zygotes, can be
offered, particularly for families with more than one
affected child.
Conclusions
Data on the frequency of WRS are sparse, and informa-
tion on this condition in KSA is limited to a few case
reports or as part of international series. However, the
available data show that KSA has the highest reported
cases of WRS worldwide, and the condition is the
commonest cause of PNDM in the country. A national
and international registry of WRS and PNDM based on
regular surveys would raise awareness of the condition,
provide accurate data, and help in clinical management.
It is also important that facilities for genetic testing for
WRS should be available for clinicians in order to
confirm the diagnosis and provide families with proper
genetic counseling.
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